NCT05270668: Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
- State
- Under way
- Phase
- Phase 2
- People
- 154 taking part
- Started
- 29 Mar 2022
- Primary completion
- 16 Apr 2026
- Arms
- Tulisokibart
- Results
- None posted
- 8 Mar 2022: Trial registered
- 29 Mar 2022: Trial started